文献速递关节外科骨质疏松与代谢性骨病

接受胰高血糖素样肽-1受体激动剂处方的患者五年内进展为骨关节炎和全关节置换术的发生率

The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists.
PubMed 文献 · J Arthroplasty · 2024-06-08

该回顾性队列研究利用协作网络分析平台,纳入2015至2017年索引就诊的肥胖糖尿病、肥胖非糖尿病和非肥胖糖尿病患者,按1:1倾向评分匹配后比较接受与未接受GLP-1-RA者的五年结局。结果显示,在肥胖糖尿病和非肥胖糖尿病队列中,GLP-1-RA使用者的髋和膝骨关节炎进展风险更高,且接受大关节注射率更高,但全髋或全膝关节置换率无差异;在肥胖非糖尿病队列中未见差异。

要点

  • 肥胖糖尿病队列中,GLP-1-RA使用者的髋OA进展风险更高(HR 1.63,95%CI 1.46-1.82),膝OA风险也更高(HR 1.52,95%CI 1.41-1.64)。
  • 非肥胖糖尿病队列中,GLP-1-RA使用者的髋OA进展风险更高(HR 1.78,95%CI 1.50-2.10),膝OA风险也更高(HR 1.58,95%CI 1.39-1.80)。
  • 糖尿病队列中GLP-1-RA使用者接受大关节注射率更高,但全髋或全膝关节置换率无差异;肥胖非糖尿病队列中未见差异。

核心结论

  • 五年分析发现,在肥胖和非肥胖糖尿病GLP-1-RA使用者中,进展为髋和膝骨关节炎的风险更高。

研究设计与样本

  • 回顾性队列研究(证据等级III),查询协作网络分析平台,纳入2015至2017年索引就诊的肥胖糖尿病(n=1,094,198)、肥胖非糖尿病(n=916,235)和非肥胖糖尿病(n=157,305)患者,排除已有髋和/或膝骨关节炎者,采用1:1倾向评分匹配平衡GLP-1-RA使用。

主要发现

  • 肥胖糖尿病队列中,GLP-1-RA使用者的髋OA进展风险更高(HR 1.63,95%CI 1.46-1.82),膝OA风险也更高(HR 1.52,95%CI 1.41-1.64)。
  • 非肥胖糖尿病队列中,GLP-1-RA使用者的髋OA进展风险更高(HR 1.78,95%CI 1.50-2.10),膝OA风险也更高(HR 1.58,95%CI 1.39-1.80)。
  • 糖尿病队列中GLP-1-RA使用者接受大关节注射率更高,但全髋或全膝关节置换率无差异。
  • 肥胖非糖尿病队列中,接受GLP-1-RA者与未暴露者的五年结局无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Research has suggested that glucagon-like peptide-1 receptor agonists (GLP-1-RAs) may have therapeutic effects on osteoarthritis of the hip and knee, in addition to managing diabetes and obesity. However, there is a lack of understanding regarding the association between GLP-1-RA use and the diagnosis of osteoarthritis (OA) of the hip and knee. METHODS: A collaborative network analytics platform was queried for obese diabetic (n = 1,094,198), obese nondiabetic (n = 916,235), and nonobese diabetic (n = 157,305) patients who had an index visit between 2015 and 2017. Patients who had pre-existing hip and/or knee OA were excluded. A 1:1 propensity score matching was used to balance GLP-1-RA use in stratified cohorts for age, sex, race, body mass index, and hemoglobin A1c. The primary outcomes were rates of progression to hip OA, knee OA, major joint injections, total hip arthroplasty, and total knee arthroplasty. Cox proportional hazards models determined hazard ratios (HRs) between cohorts prescribed and not prescribed GLP-1-RAs. RESULTS: All patients had a five-year follow-up. Rates of progression to hip and knee OA were higher among the GLP-1-RA users in both obese diabetic (hip HR: 1.63, 95% confidence interval [CI]: 1.46 to 1.82; knee HR: 1.52, CI: 1.41 to 1.64) and nonobese diabetic (hip HR: 1.78, CI: 1.50 to 2.10; knee HR: 1.58, CI: 1.39 to 1.80) cohorts. These diabetic cohorts received higher rates of major joint injections, though there was no difference in rates of total hip arthroplasty or total knee arthroplasty. No differences in five-year outcomes were seen when comparing obese, nondiabetic patients who were prescribed GLP-1-RAs with obese, nondiabetic patients not exposed to GLP-1-RAs. CONCLUSIONS: This five-year analysis found a greater risk of progression to hip and knee OA among obese and non-obese diabetic GLP-1-RA users. Further studies should explore GLP-1-RA effects upon glucose management, weight loss, and lower extremity arthritis development. LEVEL OF EVIDENCE: III, retrospective cohort study.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Lavu MS, Porto JR, Hecht CJ, et al. The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists. J Arthroplasty. 2024. PMID: 38857711. doi:10.1016/j.arth.2024.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。